DRUG Long Put Strategy

DRUG (Bright Minds Biosciences Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

DRUG (Bright Minds Biosciences Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $776.8M, a beta of 0.09 versus the broader market, a 52-week range of 38-123.75, average daily share volume of 276K, a public-listing history dating back to 2021, approximately 26 full-time employees. These structural characteristics shape how DRUG stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.09 indicates DRUG has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long put on DRUG?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

DRUG snapshot

As of August 14, 2026, spot at $76.75, ATM IV 67.60%, expected move 19.38%. The long put on DRUG below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long put structure on DRUG specifically: IV rank is unavailable in the current snapshot, so regime-based timing for DRUG is inferred from ATM IV at 67.60% alone, with a market-implied 1-standard-deviation move of approximately 19.38% (roughly $14.87 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DRUG expiries trade a higher absolute premium for lower per-day decay. Position sizing on DRUG should anchor to the underlying notional of $76.75 per share and to the trader's directional view on DRUG stock.

DRUG long put setup

The DRUG long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DRUG at $76.75 on that close, the first option leg uses a $76.75 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DRUG chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DRUG shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$76.75N/A

DRUG long put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

DRUG long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on DRUG. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long put on DRUG

Long puts on DRUG hedge an existing long DRUG stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying DRUG exposure being hedged.

DRUG thesis for this long put

The market-implied 1-standard-deviation range for DRUG extends from approximately $61.88 on the downside to $91.62 on the upside. A DRUG long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long DRUG position with one put per 100 shares held. As a Healthcare name, DRUG options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DRUG-specific events.

DRUG long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DRUG positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DRUG alongside the broader basket even when DRUG-specific fundamentals are unchanged. Long-premium structures like a long put on DRUG are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DRUG chain quotes before placing a trade.

Frequently asked questions

What is a long put on DRUG?
A long put on DRUG is the long put strategy applied to DRUG (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With DRUG stock at $76.75 on the most recent close, the strikes shown on this page are snapped to the nearest listed DRUG chain strike and the premiums come straight from that session's bid/ask midpoint.
How are DRUG long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the DRUG long put priced from the end-of-day chain at a 30-day expiry (ATM IV 67.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a DRUG long put?
The breakeven for the DRUG long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The DRUG market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.38%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on DRUG?
Long puts on DRUG hedge an existing long DRUG stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying DRUG exposure being hedged.
How does current DRUG implied volatility affect this long put?
Current DRUG ATM IV is 67.60%; IV rank context is unavailable in the current snapshot.

Related DRUG analysis